AU765990B2 - Structural models for cytoplasmic domains of transmembrane receptors - Google Patents

Structural models for cytoplasmic domains of transmembrane receptors Download PDF

Info

Publication number
AU765990B2
AU765990B2 AU51773/00A AU5177300A AU765990B2 AU 765990 B2 AU765990 B2 AU 765990B2 AU 51773/00 A AU51773/00 A AU 51773/00A AU 5177300 A AU5177300 A AU 5177300A AU 765990 B2 AU765990 B2 AU 765990B2
Authority
AU
Australia
Prior art keywords
paxillin
polypeptide
cytoplasmic domain
integrin
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU51773/00A
Other languages
English (en)
Other versions
AU5177300A (en
Inventor
Mark H. Ginsberg
Shouchun Liu
Martin Pfaff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5177300A publication Critical patent/AU5177300A/en
Assigned to GINSBERG, MARK H. reassignment GINSBERG, MARK H. Alteration of Name(s) of Applicant(s) under S113 Assignors: SCRIPPS RESEARCH INSTITUTE, THE
Application granted granted Critical
Publication of AU765990B2 publication Critical patent/AU765990B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/7055Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
AU51773/00A 1999-06-01 2000-06-01 Structural models for cytoplasmic domains of transmembrane receptors Ceased AU765990B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32344799A 1999-06-01 1999-06-01
US09/323447 1999-06-01
PCT/US2000/015153 WO2000073342A1 (en) 1999-06-01 2000-06-01 Structural models for cytoplasmic domains of transmembrane receptors

Publications (2)

Publication Number Publication Date
AU5177300A AU5177300A (en) 2000-12-18
AU765990B2 true AU765990B2 (en) 2003-10-09

Family

ID=23259240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51773/00A Ceased AU765990B2 (en) 1999-06-01 2000-06-01 Structural models for cytoplasmic domains of transmembrane receptors

Country Status (5)

Country Link
EP (1) EP1180122A4 (ja)
JP (1) JP2003504308A (ja)
AU (1) AU765990B2 (ja)
CA (1) CA2374133A1 (ja)
WO (1) WO2000073342A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112738A1 (en) * 2005-04-19 2006-10-26 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disorders
WO2008061563A1 (de) * 2006-11-22 2008-05-29 Aplagen Gmbh Peptide für die behandlung der multiplen sklerose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUIR ET AL (1994) BIOCHEM 33: 7701-8 *
PFAFF ET AL (1998) J.BIOL CHEM 273 6104-9 *

Also Published As

Publication number Publication date
EP1180122A1 (en) 2002-02-20
EP1180122A4 (en) 2003-03-26
JP2003504308A (ja) 2003-02-04
CA2374133A1 (en) 2000-12-07
AU5177300A (en) 2000-12-18
WO2000073342A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
Kishore et al. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains
O'Toole et al. Integrin cytoplasmic domains mediate inside-out signal transduction
Li et al. Structure of the conserved cytoplasmic C-terminal domain of occludin: identification of the ZO-1 binding surface
Prodromou et al. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone
Geiger et al. Cytohesin-1 regulates β-2 integrin-mediated adhesion through both ARF-GEF function and interaction with LFA-1
Arpin et al. Functional differences between L-and T-plastin isoforms.
JP3560344B2 (ja) プロトカドヘリンタンパク質およびその使用
Schraw et al. A role for Sec1/Munc18 proteins in platelet exocytosis
CA2324381C (en) An integrin heterodimer and a subunit thereof
KR20200032184A (ko) 환상 펩티드를 단백질 구조에 제시시키는 초범용법
US20030113828A1 (en) Compositions and methods for modulating Syk function
Bennasroune et al. Inhibition by transmembrane peptides of chimeric insulin receptors
Kashiwagi et al. Affinity modulation of platelet integrin ɑIIbß3 by ß3-endonexin, a selective binding partner of the ß3 integrin cytoplasmic tail
US6303317B1 (en) Peptide probes and methods for making the same
EP0804728A1 (en) Assay, receptor proteins and ligands
Andersen et al. Annexin-V binds to the intracellular part of the β5 integrin receptor subunit
WO1998032848A9 (en) Peptide probes to coil proteins and methods for making the same
AU765990B2 (en) Structural models for cytoplasmic domains of transmembrane receptors
EP1200588B1 (en) Single-chain polypeptides comprising troponin i n-terminal fragments and troponin c
KR20190138648A (ko) 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
WO1998032771A1 (fr) Proteines chimeres, complexes heterodimeres de ces proteines et substituant de plaquette
Kalinin et al. Breaking the connection: caspase 6 disconnects intermediate filament-binding domain of periplakin from its actin-binding N-terminal region
AU755574B2 (en) Synthetic peptide immunogens and antibodies thereto
US20020198360A1 (en) Structural models for cytoplasmic domains of transmembrane receptors
EP0835319A1 (en) INTERACTION OF p53 WITH TRANSCRIPTION FACTOR DP-1

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MARK H. GINSBERG

Free format text: THE FORMER OWNER WAS: THE SCRIPPS RESEARCH INSTITUTE

FGA Letters patent sealed or granted (standard patent)